Compare RLI & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLI | FOLD |
|---|---|---|
| Founded | 1965 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.5B |
| IPO Year | 1994 | 2006 |
| Metric | RLI | FOLD |
|---|---|---|
| Price | $57.31 | $14.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $62.40 | $27.25 |
| AVG Volume (30 Days) | 511.3K | ★ 2.3M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.52% | N/A |
| EPS Growth | 16.84 | ★ 50.00 |
| EPS | ★ 4.37 | N/A |
| Revenue | ★ $1,882,448,000.00 | N/A |
| Revenue This Year | N/A | $20.50 |
| Revenue Next Year | $3.53 | $18.59 |
| P/E Ratio | $13.39 | ★ N/A |
| Revenue Growth | ★ 6.33 | N/A |
| 52 Week Low | $55.80 | $5.66 |
| 52 Week High | $78.25 | $14.48 |
| Indicator | RLI | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 64.82 |
| Support Level | $55.86 | $14.21 |
| Resistance Level | $59.31 | $14.48 |
| Average True Range (ATR) | 1.21 | 0.02 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 18.86 | 60.00 |
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety, and it derives a majority of its revenue from the Casualty segment.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.